Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers - Wikidata - wikimedia - TriplyDB

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

http://www.wikidata.org/entity/Q28375856

about

The HER2 Receptor in Breast Cancer: Pathophysiology, Clinical Use, and New Advances in Therapy Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors EGFR/HER-targeted therapeutics in ovarian cancer Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells.Twenty years of anti-HER2 therapy-associated cardiotoxicity From bench to bedside: lessons learned in translating preclinical studies in cancer drug development Vinorelbine plus 3-weekly trastuzumab in metastatic breast cancer: a single-centre phase 2 trial Predicting for activity of second-line trastuzumab-based therapy in her2-positive advanced breast cancer.A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer.Role of HER2 gene overexpression in breast carcinoma.In vitro selection of RNA aptamer and specific targeting of ErbB2 in breast cancer cells.Persistent expression of biologically active anti-HER2 antibody by AAVrh.10-mediated gene transfer The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity Drug-induced ubiquitylation and degradation of ErbB receptor tyrosine kinases: implications for cancer therapy.The Role of Supportive Therapy in the Era of Modern Adjuvant Treatment - Current and Future Tools.Development of inhibitors for protein tyrosine kinases.Anti-HER2 vaccines: new prospects for breast cancer therapy Increased choline kinase activity in human breast carcinomas: clinical evidence for a potential novel antitumor strategy.Anti-tumor effects of retinoids combined with trastuzumab or tamoxifen in breast cancer cells: induction of apoptosis by retinoid/trastuzumab combinations.STAT proteins: novel molecular targets for cancer drug discovery.Addition of GM-CSF to trastuzumab stabilises disease in trastuzumab-resistant HER2+ metastatic breast cancer patients Current status of anti-human epidermal growth factor receptor 2 therapies: predicting and overcoming herceptin resistance Immune therapy for breast cancer in 2010-hype or hope?Anti-human epidermal growth factor receptor 2 monoclonal antibody therapy for breast cancer.Amplification of HER-2 in gastric carcinoma: association with Topoisomerase IIalpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab.Oxaliplatin: a review of evolving concepts.Primary trastuzumab resistance: new tricks for an old drug.A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01).HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies.Trastuzumab increases the sensitivity of HER2-amplified human gastric cancer cells to oxaliplatin and cisplatin by affecting the expression of telomere-associated proteins Trastuzumab beyond progression in HER2-positive advanced breast cancer: the Royal Marsden experience.Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3.Ansamycin antibiotics inhibit Akt activation and cyclin D expression in breast cancer cells that overexpress HER2.Clinical experience with trastuzumab (herceptin).Combining emerging agents in advanced breast cancer Anti-erbB2 treatment induces cardiotoxicity by interfering with cell survival pathways Trastuzumab-based combination therapy for breast cancer.Systemic therapy for advanced breast cancer.Adjuvant trastuzumab in HER2-positive breast cancer.ER, PgR, Ki67, p27(Kip1), and histological grade as predictors of pathological complete response in patients with HER2-positive breast cancer receiving neoadjuvant chemotherapy using taxanes followed by fluorouracil, epirubicin, and cyclophosphamide

P2860

Q21284978-80C1A50A-3667-48A9-9751-283A0C8646CF Q24626904-1D832334-1A33-41BF-9216-EC09DF979129 Q26863231-45D58B79-F830-446B-9E9D-0F5BDF0280A9 Q27824846-3CC43A81-D405-4D70-B03C-EA64FE829725 Q28079391-A2FEF74F-60F4-4255-B211-6C4D0EDABE23 Q28533949-DCF3C27E-A3BE-4E39-B38A-B7F262234B13 Q33279460-27FC153E-6A45-4D8A-812F-0EEC57586452 Q33511035-3D866A12-6A68-4DB1-BF9A-5DB7D19D8EF4 Q33651496-C5B3BDE3-3D51-42D3-9621-976249E56842 Q33810080-7AE8E58F-6D85-4A64-B6FD-D7FF44A388FE Q33958666-3F58554C-9FF1-4534-84E4-AD615D9B7122 Q34005560-F5FF6CC2-2268-47CB-B754-70D9847BF862 Q34073138-B9BA6CC5-5C4C-4A51-9C5C-C1DBA9A89D8C Q34088024-2106C2A5-D3AB-40DB-8935-1708B8EEF177 Q34095827-BF4C43AD-DE79-466C-A333-88F5A413A9D5 Q34103669-373E5B00-C453-4238-AAED-145C5CEDB5AC Q34105959-DC0A95EB-46C8-46E5-AA4B-766FD080BA51 Q34135239-A17148C9-04A0-410D-A8B4-0142C35204BF Q34173557-A82700C9-3A6A-4C82-89AB-A0564D214B14 Q34293579-408EC3D5-7980-4D58-80C6-43BC158613A8 Q34344146-04CC26A0-9811-48CF-A899-8F4910A691E0 Q34355748-AB26CE47-5CC9-4A7D-99CF-E81B04ED3B1B Q34541467-3C28EAE1-A1D1-4300-9F0C-A002F3A6E889 Q34548277-44B7393E-2B8C-4FB9-BCC4-216174286B91 Q34554455-59863A55-3539-457C-90D3-E387B150D193 Q34569008-22AE7908-FADB-4102-AC54-7D164B25EC70 Q34610251-E1C7B3AA-5F7B-4EC1-986C-37A0AD7F32A2 Q34635509-0522A991-A314-4B67-B383-9E665F62E14D Q34974436-4E2555ED-7A31-4350-BD2D-AB81788424FA Q34993878-50BE8941-E599-4D02-995E-F190E3C5F3E8 Q35034559-6D3C9DE9-7CFA-47B5-8912-923B120504F9 Q35234347-7EBDFE2B-621C-4B6C-99AA-88991ED2FEF2 Q35564020-9BF4CD36-EA89-4403-A49A-84A0569BB28E Q35583405-03E6031F-4038-4451-945E-63353DA51BCB Q35584962-9F70AE0E-C364-438D-B547-827A19E82434 Q35605824-F1E54CED-70A5-4621-ACB9-F874A94AD021 Q35609686-57B3225A-D036-4770-8B9E-0012E4BA3F4D Q35675858-7DDCF66C-B0F8-44D1-AF08-8B59163601F6 Q35710898-38F1A161-BBFA-4F9B-862B-9D5192343BA9 Q35765844-2E98AECC-AA49-4A3C-B0EE-61F16B7083A9

P2860

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

http://www.wikidata.org/entity/Q28375856

description

1999 nî lūn-bûn

@nan

1999 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1999 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1999年の論文

@ja

1999年論文

@yue

1999年論文

@zh-hant

1999年論文

@zh-hk

1999年論文

@zh-mo

1999年論文

@zh-tw

1999年论文

@wuu

name

Inhibitory effects of combinat ...... atment of human breast cancers

@ast

Inhibitory effects of combinat ...... atment of human breast cancers

@en

Inhibitory effects of combinat ...... atment of human breast cancers

@nl

type

label

Inhibitory effects of combinat ...... atment of human breast cancers

@ast

Inhibitory effects of combinat ...... atment of human breast cancers

@en

Inhibitory effects of combinat ...... atment of human breast cancers

@nl

prefLabel

Inhibitory effects of combinat ...... atment of human breast cancers

@ast

Inhibitory effects of combinat ...... atment of human breast cancers

@en

Inhibitory effects of combinat ...... atment of human breast cancers

@nl

P1433

Q28375856-C93736CF-7ADD-42B4-BAA0-1E20CC316E29

P1476

Q28375856-784AEEE1-E665-4974-9CF5-ACCE8D526B09

P2093

Q28375856-064E89B6-5CF0-4C6B-841E-FB2993A6904D

Q28375856-2B4CBE76-F068-43D0-96F0-4260DE03456D

Q28375856-3ECEAB38-5D15-4F5A-A76E-0DBD6A12E303

Q28375856-4DAC7CEF-6C1F-4A00-8B77-6950BF8669EA

Q28375856-5AB9A01E-B220-4123-AD2D-D3B19D53738E

Q28375856-64562332-7AF9-4548-940E-CF30291A6143

Q28375856-9486FB6A-9695-4C64-8DFB-95D61A36FA07

Q28375856-9939E81B-B8D7-43D9-9285-D891D4C848EA

Q28375856-D8B88FC3-8620-4509-BAFC-7DB808EEBC2D

Q28375856-E613B54F-BC9B-4235-9DDD-A6DF03B7361F

P2860

Q28375856-10217751-00AA-4B3E-9326-CFC2DAA419DE

Q28375856-143C33C3-0902-4841-9943-A6A6E2E4D497

Q28375856-1FD44F47-E430-4487-AFB3-EBC2B7B9F24F

Q28375856-26DF0355-382A-4C63-BAC8-B0A4CECBB540

Q28375856-4D21D101-F68D-4033-9C16-0DF1D05477CE

Q28375856-4E908427-557C-4114-8348-40C6498E0E2D

Q28375856-5345F630-79D6-4A73-B32D-B2609C7EF193

Q28375856-59638086-A52C-461B-A2BF-6B9B758C6ED7

Q28375856-5E57CA62-38F3-44F1-9420-892062F0C55B

Q28375856-6511236E-655C-4900-B754-80FDF35DCB90

P2888

Q28375856-B8562ADA-988D-4E40-BDEE-CC4745E89ECE

P304

Q28375856-69A76086-055A-4F97-87DC-C4BE845AF34D

P31

Q28375856-E3DAD666-CC02-4177-A434-11578559AA63

P3181

Q28375856-0E8D02CF-8B62-4277-9444-D4223902BAF9

P356

Q28375856-A72D3DB8-6266-41F4-A942-13DC448ACA3D

P407

Q28375856-8CA50C61-29A6-4E03-9720-788648EB9E57

P433

Q28375856-7212587F-7AEE-4864-861A-AA3FDCDD3A9D

P478

Q28375856-84BC3B20-39BE-44FD-8B3C-C4EAA3BB48DA

P577

Q28375856-A6357ED5-5C69-4FF8-9C9B-EF716CECA202

P5875

Q28375856-A5D93CC9-3B36-48F8-9730-449D7CFEE1CF

P6179

Q28375856-7DB1EBEA-DAC7-45F2-97CA-C15A9226BC71

P698

Q28375856-A6ECB3B6-F5D6-484F-AB18-BBABC575B327

P921

Q28375856-36D07D87-EF61-4EEF-BCA0-CBF5E68681B8

Q28375856-C49F2258-3446-4A09-BA5F-2EA3660F0B76

P3181

P356

P1433

P1476

Inhibitory effects of combinat ...... atment of human breast cancers

@en

P2093

D Baly

http://www.w3.org/2001/XMLSchema#string

D Coombs

http://www.w3.org/2001/XMLSchema#string

D Slamon

http://www.w3.org/2001/XMLSchema#string

F Kabbinavar

http://www.w3.org/2001/XMLSchema#string

G Lewis

http://www.w3.org/2001/XMLSchema#string

M Beryt

http://www.w3.org/2001/XMLSchema#string

M Pegram

http://www.w3.org/2001/XMLSchema#string

M Sliwkowski

http://www.w3.org/2001/XMLSchema#string

R Pietras

http://www.w3.org/2001/XMLSchema#string

S Hsu

http://www.w3.org/2001/XMLSchema#string

P2860

Identification of heregulin, a specific activator of p185erbB2

Humanization of an anti-p185HER2 antibody for human cancer therapy

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma in vitro and in nude mice.

A v-erbB-related protooncogene, c-erbB-2, is distinct from the c-erbB-1/epidermal growth factor-receptor gene and is amplified in a human salivary gland adenocarcinoma

p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor.

Agonistic antibodies stimulate the kinase encoded by the neu protooncogene in living cells but the oncogenic mutant is constitutively active

The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.

P2888

P304

2241-51

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3980864

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/SJ.ONC.1202526

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

1999-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12971767

http://www.w3.org/2001/XMLSchema#string

P6179

1001624052

http://www.w3.org/2001/XMLSchema#string

P698

10327070

http://www.w3.org/2001/XMLSchema#string

P921